For STAT News, Joanne Silberner (@jsilberner) reports on the role of a medication’s efficacy and R&D costs in its eventual price, and what role this might play in Medicare’s newly granted authority to negotiate prices. She discusses new research that reveals the role of effectiveness and R&D on the price that manufacturers set (spoiler: none) and talks to experts about how drugs get priced and what power Medicare might have to get the government a better deal. Photo: Pöllö via Wikimedia Commons
